Zentalis Pharmaceuticals (ZNTL) Cash from Financing Activities (2019 - 2026)

Zentalis Pharmaceuticals' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at -$1.1 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 694.18% year-over-year to -$1.1 million in Q1 2026; TTM through Mar 2026 was -$5.6 million, a 2028.97% decrease from a year earlier, with the FY2025 full-year figure at -$4.3 million, down 4064.81% from the prior year.
• Cash from Financing Activities climbed to -$1.1 million in Q1 2026 per ZNTL's latest filing, from -$4.6 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $236.6 million in Q2 2023 and bottomed at -$4.6 million in Q4 2025.
• The 5-year median for Cash from Financing Activities is $249000.0 (2023), against an average of $35.2 million.
• Across the five-year window, Cash from Financing Activities surged 66383.23% in 2022 and slumped 694.18% in 2026, its largest moves.
• Year by year, Cash from Financing Activities stood at $49.7 million in 2022, then tumbled by 99.38% to $309000.0 in 2023, then slumped by 70.23% to $92000.0 in 2024, then plunged by 5084.78% to -$4.6 million in 2025, then jumped by 75.51% to -$1.1 million in 2026.
• Per Business Quant, the three latest ZNTL Cash from Financing Activities figures stand at -$1.1 million (Q1 2026), -$4.6 million (Q4 2025), and $115000.0 (Q3 2025).